Stub

Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.

CE & Ipilimumab

back to top

CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab

Regimen

Chemotherapy

• Carboplatin (Paraplatin)
• Etoposide (Vepesid)

Immunotherapy

• Ipilimumab (Yervoy)

CE & Thalidomide

back to top

CE & Thalidomide: Carboplatin, Etoposide, Thalidomide

Regimen

Chemotherapy

• Carboplatin (Paraplatin)
• Etoposide (Vepesid)

Targeted therapy

• Thalidomide (Thalomid)

EP & Ipilimumab

back to top

EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab

Regimen

Chemotherapy

• Etoposide (Vepesid)
• Cisplatin (Platinol)

Immunotherapy

• Ipilimumab (Yervoy)

EP, Tamoxifen, RT

back to top

EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy

Regimen

Chemotherapy

• Etoposide (Vepesid)
• Cisplatin (Platinol)

Hormonotherapy

• Tamoxifen (Nolvadex)

Radiotherapy

• Concurrent thoracic radiation therapy

Ixabepilone & Bevacizumab

back to top

Regimen

Chemotherapy

• Ixabepilone (Ixempra)

Targeted therapy

• Bevacizumab (Avastin)

TG+Bev

back to top

TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab

Regimen

Chemotherapy

• Docetaxel (Taxotere)
• Gemcitabine (Gemzar)

Targeted therapy

• Bevacizumab (Avastin)

TX+Bev

back to top

TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab

Regimen

Chemotherapy

• Docetaxel (Taxotere)
• Capecitabine (Xeloda)

Targeted therapy

• Bevacizumab (Avastin)